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Background: In cystic fibrosis (CF), the spectrum and frequency of CFTR variants
differ by geography and race/ethnicity. CFTR variants in White patients are well‐
described compared with Latino patients. No studies of CFTR variants have been done
in patients with CF in the Dominican Republic or Puerto Rico.
Methods: CFTR was sequenced in 61 Dominican Republican patients and 21 Puerto
Rican patients with CF and greater than 60mmol/L sweat chloride. The spectrum of
CFTR variants was identified and the proportion of patients with 0, 1, or 2 CFTR
variants identified was determined. The functional effects of identified CFTR
variants were investigated using clinical annotation databases and computational
prediction tools.
Results: Our study found 10% of Dominican patients had two CFTR variants
identified compared with 81% of Puerto Rican patients. No CFTR variants were
identified in 69% of Dominican patients and 10% of Puerto Rican patients. In
Dominican patients, there were 19 identified CFTR variants, accounting for 25
out of 122 disease alleles (20%). In Puerto Rican patients, there were 16
identified CFTR variants, accounting for 36 out of 42 disease alleles (86%) in
Puerto Rican patients. Thirty CFTR variants were identified overall. The most
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frequent variants for Dominican patients were p.Phe508del and p.Ala559Thr and
for Puerto Rican patients were p.Phe508del, p.Arg1066Cys, p.Arg334Trp, and
p.I507del.
Conclusions: In this first description of the CFTR variants in patients with CF from the
Dominican Republic and Puerto Rico, there was a low detection rate of two CFTR
variants after full sequencing with the majority of patients from the Dominican
Republic without identified variants.
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1 | INTRODUCTION
Although the majority of the 80 000 people worldwide with cystic
fibrosis (CF) are White, an increasing proportion of patients are of
other races and ethnicities. In the United States (U.S.), the percentage
of patients with CF who are Latino increased from 5.6% to 8.7% over
the past 15 years.1 The increase in the Latino CF population is
important as these patients have increased morbidity and mortality
compared with the White CF population.2,3
Latino patients not only have a different clinical course than
White patients, but they also have different CFTR variants.4 Latino
patients are also more likely to have CFTR Class IV to V or
uncharacterized variants whereas White patients are more likely to
have Class I to III variants. Latino patients are more likely to have one
or no CFTR variants identified, in part due to CF genetic panels and
newborn screens having lower sensitivity to variants that are more
common in the Latino population.5
CFTR variants are population‐specific and the spectrum of known
CFTR variants is based largely on investigations of White popula-
tions.6 Even among investigations of Latino populations, there have
been limited efforts to describe the genetic profile of CF in the
Caribbean.7 There is considerable genetic heterogeneity between
Latino populations and within the Caribbean.8
In this study, full genetic sequencing of CFTR was done in
Dominican and Puerto Rican patients with CF to describe the
spectrum of CFTR variants. The proportion of patients with 0, 1, or 2
CFTR variants identified was determined. The functional impact of
each identified CFTR variant was classified based on clinical
databases and deleteriousness prediction algorithms.
2 | METHODS
2.1 | Study population
This was a cross‐sectional study of CFTR variants in patients with CF
in the Dominican Republic and Puerto Rico. All patients had a
diagnosis of CF made by their clinical doctor based on the presence
of clinical CF symptoms and a positive sweat chloride concentration
(>60mmol/L) based on Cystic Fibrosis Foundation guidelines.9
Patients with an intermediate sweat chloride concentration
(<60mmol/L) were not included in our study. Patients 6 years of
age and older were recruited from CF clinics in the Dominican
Republic and Puerto Rico in 2017. Consent and assent were obtained
from patients and their guardians as appropriate. This study was
approved by the Western Institutional Review Board.
At the time of recruitment, CFTR variants identified through prior
genotyping, sweat chloride concentration, demographic data, pan-
creatic sufficiency status, and pulmonary function percent predicted
based on Global Lung Initiative was recorded for each patient. Blood
was drawn for genetic analysis.
2.2 | Whole genome sequencing analysis
DNA was isolated from whole blood using the Wizard Genomic DNA
Purification kits (Promega, Fitchburg, WI). DNA samples were
quantified by fluorescence using the Quant‐iT PicoGreen dsDNA
assay (Thermo Fisher Scientific, Waltham, MA) on a Spectramax
fluorometer (Molecular Devices, Sunnyvale, CA). DNA samples were
sequenced as part of the Trans‐Omics for Precision Medicine
(TOPMed) whole genome sequencing (WGS) program.9 WGS was
performed at the Northwest Genomics Center on a HiSeqX system
(Illumina, San Diego, CA) using a paired‐end read length of 150 base
pair, to a minimum of 30× mean genome coverage. Details on DNA
sample handling, quality control, library construction, clustering and
sequencing, read processing, and sequence data quality control are
previously described.10 Variant calls were obtained from TOPMed
data freeze 8 variant call format files. The term “variant” is used in
place of “mutation” or “polymorphism”.11 Variants with a minimal
depth of coverage of 10 reads were included in our analyses.
Variants were annotated in TOPMed using the WGSA pipeline.12
CFTR variants were annotated with reference to the NM_000492.3
transcript. Genetic variants in CFTRwere extracted (ENSG00000001626;
ENST00000003084) from chr7:117,465,784‐117,715,971, which in-
cluded segments 15 kb upstream of the CFTR transcription start site
and 47 kb downstream of the last exon. Sequences aligned to hs38DH
1000 Genomes GRCh38/hg38 reference assembly using BWA‐MEM
were received as CRAM files from TOPMed.13 Chromosome 7 sequence
reads were extracted from the CRAM files using Samtools v1.9.14 Copy
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number variation was detected using a bin size of 500 with CNVnator
v0.3.3.15 Structural variation in chromosome 7, including deletions,
duplications, inversions, and translocations, were detected with LUMPY
express v0.2.13.16 The sequencing quality of variants that did not have
value “PASS” in the FILTER field from TOPMed was checked by manual
inspection of the sequencing reads alignment using Integrative Genome
Viewer. Other possible FILTER values include centromere (variant
overlaps with centromeric region), SVM (variant failed SVM filter), and
duplicate discordances (variant with high mendelian or duplicate
genotype discordance [3/5% or more]).10
Phased genotypes from TOPMed data freeze 8 were used to
determine whether two variants are in cis or trans (see section
below).17 These were statistically phased by applying Eagle 2.4 (Dec
13, 2017) to the whole panel of 137 977 samples included in
TOPMed freeze 8. Phasing was done in 1Mb chunks with 0.1Mb
overlap. The entire CFTR locus (chr7:117,465,784‐117,715,971) falls
within a single chunk. Phasing was limited to variants which pass all
filters and starts with minDP10 genotypes to restrict to high quality
genotypes. Phasing imputes any missing genotypes. Statistical
phasing has limited accuracy for very rare variants (those seen in
fewer than five individuals in the panel).18
2.3 | Clinical annotations of variants
To determine the clinical impact of CFTR variants identified by
sequencing, variants were first compared with the Clinical and
Functional Translation of CFTR (CFTR2) database.19 The CFTR2
database provides functional classifications for variants with clinical
and laboratory evidence of phenotypic consequence. These classifi-
cations include “CF‐causing,” “varying clinical consequence,” “un-
known significance,” and “non‐CF‐causing.” CFTR variants identified
by sequencing that were not listed in the CFTR2 database were
analyzed to identify common variants, defined by an allele frequency
greater than 3% on Genome Aggregation Database (gnomAD) in the
general non‐CF population.9 Variants that are common in a non‐CF
population are unlikely to be disease‐causing. All identified variants
that were not in the CFTR2 database or had an allele frequency less
than 3% were cross‐referenced with two variant databases, ClinVar
and Invitae, to determine the functional impact of the variant.
ClinVar is a publicly available repository of genotype‐phenotype
investigations.20 Invitae is a clinical genetic sequencing laboratory.21
Variants in the ClinVar and Invitae databases were annotated as
“pathogenic,” “likely pathogenic,” “uncertain significance,” or “benign.”
Genetic variants without clinical annotations in the CFTR2,
ClinVar, or Invitae databases were analyzed for deleteriousness using
three computational prediction algorithms: Combined Annotation
Dependent Depletion (CADD), FATHMM‐XF, and Rare Exome
Variant Ensemble Learner (REVEL).22-24 Variants predicted to be
deleterious had a scaled C‐score ranking from CADD >16 or were
predicted to be likely damaging by FATHMM‐XF or had a REVEL
score greater than 0.5.
Variants were categorized into five functional classifications
based on databases and computational predictions as follows:
(a) CF‐disease causing variant, (b) variant of varying clinical
consequence, (c) variant of uncertain significance, (d) variant
predicted to be deleterious, and (e) Non‐CF‐disease causing or likely
benign variant (Figure 1).
The CFTR variants and genotype for each patient were
determined. In patients with two variants, the phased genotype
(variants in cis or trans) was assessed using BCFtools.25 Patients were
categorized as fully identified CFTR genotype (two variants in trans)
versus those who were not (with two variants in cis, one variant, or
no variants).
3 | RESULTS
3.1 | Genotyping results before recruitment
Our study population consisted of 82 patients diagnosed with CF
from the Dominican Republic (N = 61) and Puerto Rico (N = 21). At
recruitment, 3% of Dominican patients had two identified CFTR
variants, 3% had one variant, and 93% had not been genetically
tested for CF. Among Puerto Rican patients, 57% of patients had two
identified CFTR variants, 24% had one variant, 5% had no variants,
and 14% had not been tested.
At the time of recruitment, Dominican patients were a median
age of 10.6 years old and Puerto Rican patients were 15.4 years old.
The majority of Dominican patients (86.9%) and Puerto Rican
patients (81.0%) were pancreatic insufficient. The predicted percen-
tage of average forced expiratory volume in 1 second was 91.7% in
Dominican patients and was 83.4% in Puerto Rican patients.
3.2 | WGS results
There were 1568 CFTR variants identified by WGS in our
study population (Figure 1). No structural variation or copy
number variation was detected in the CFTR region
(ENSG00000001626; chr7:117,465,784‐117,715,971). Of the
1568 variants identified, 29 variants were functionally classified
in the CFTR2 database: 16 CF‐disease causing variants, four
varying clinical consequence variants, two variants of uncertain
significance, and seven non‐CF‐causing variants. Of the 1539
CFTR variants not present in the CFTR2 database, 397 were
identified as common variants in the general population, there-
fore were interpreted as benign and not analyzed further. Of the
remaining 1142 variants, functional classification using the
ClinVar and Invitae databases was determined in 30 variants:
one CF‐disease causing variant, four variants of uncertain
significance, and 25 likely benign variants. There was no
functional classification description for the 1112 remaining
variants, so they were further annotated using three functional
prediction algorithms. Seven variants were predicted to be
deleterious by at least one computational prediction tool. Three
of these seven variants were removed after manual inspection of
the sequencing reads alignment suggested these were sequencing
or alignment errors.
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F IGURE 1 Flowchart for assignment of CFTR variant categories. CF, cystic fibrosis [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 Known disease‐causing CFTR variants
# Protein name cDNA name Position (GRCh38) Reference allele Alternate allele
Occurrences, n (%)
D.R. P.R.
1 p.Phe508del c.1521_1523delCTT 7:117559590 ATCT A 6 (10%) 7 (33%)
2 p.Arg1066Cys c.3196C>T 7:117611637 C T ‐‐‐ 7 (33%)
3 p.Arg334Trp c.1000C>T 7:117540230 C T 1 (2%) 3 (14%)
4 p.Ile507del c.1519_1521delATC 7:117559586 TATC T ‐‐‐ 3 (14%)
5 p.Gly542* c.1624G>T 7:117587778 G T ‐‐‐ 2 (10%)
6 ‐‐‐ c.1680‐886A>G 7:117589467 A G ‐‐‐ 2 (10%)
7 p.Asn1303Lys c.3909C>G 7:117652877 C G ‐‐‐ 2 (10%)
8 p.Arg553* c.1657C>T 7:117587811 C T 1 (2%) 1 (5%)
9 ‐‐‐ c.2988 + 1G>A 7:117606754 G A 1 (2%) 1 (5%)
10 p.Ala559Thr c.1675G>A 7:117587829 G A 2 (3%) ‐‐‐
11 ‐‐‐ c.164 + 1G>A 7:117504364 G A ‐‐‐ 1 (5%)
12 p.Tyr1092* c.3276C>A 7:117611717 C A ‐‐‐ 1 (5%)
13 ‐‐‐ c.3368‐2A>G 7:117614611 A G ‐‐‐ 1 (5%)
14 p.Thr1220fs c.3659delC 7:117627711 AC A ‐‐‐ 1 (5%)
15 p.Ile148fs c.442delA 7:117531067 CA C 1 (2%) ‐‐‐
16 p.Arg709* c.2125C>T 7:117592292 C T 1 (2%) ‐‐‐
Abbreviations: cDNA, complementary DNA; D.R., Dominican Republic; P.R., Puerto Rico.
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Overall, we identified 30 CFTR variants as follows: 16 CF‐disease
causing variants (Table 1), four variants of varying clinical conse-
quence, six variants of uncertain significance, and four variants
predicted to be deleterious (Table 2). The most frequent known
disease‐causing variants for Dominican patients were p.Phe508del
(10%) and p.Ala559Thr (3%). The most frequent known disease‐
causing variants for Puerto Rican patients were p.Phe508del (33%),
p.Arg1066Cys (33%), p.Arg334Trp (14%), and p.Ile507del l (14%).
Only 10% of Dominican patients had two CF‐disease causing
variants in trans compared with 81% of Puerto Rican patients
(Table 3). Both Dominican patients (10%) and Puerto Rican patients
(10%) had multiple CFTR variants in cis. Eleven percent of Dominican
patients had only one CFTR variant identified; no Puerto Rican patients
had only one CFTR variant identified. No variants were identified in
69% of Dominican patients and in 10% of Puerto Rican patients.
The 30 identified CFTR variants accounted for 25 out of 122
disease alleles (20%) in Dominican patients and 36 out of 42 disease
alleles (86%) in Puerto Rican patients.
4 | DISCUSSION
In this first genetic description of CFTR variants in Dominican and Puerto
Rican patients with CF, we found that there was a low rate of patients
having two CFTR variants identified after full sequencing. The spectrum of
CFTR variants differed between the two populations, which are of the
same ethnicity in close geographic proximity. In the overall CF population
in the U.S., 86% of patients have at least one copy of p.Phe508del. In
contrast, in our study, only 9.8% of Dominican patients and 33% of
Puerto Rican patients had at least one copy of p.Phe508del.1 The most
frequent variants we found in Puerto Rican patients occurred at low rates
in the general CF population in the U.S.: p.Ile507del is the 15th most
common variant occurring in 0.8% of the general CF population but was
observed in 14% of Puerto Rican patients in our study; p.Arg334Trp is
the 25th most common variant occurring in 0.3% of the general CF
population but was observed in 14% of Puerto Rican patients and 3% of
Dominican patients in our study. p.Arg1066Cys was observed in a third
of Puerto Rican patients in our study but is not in the top 25 most
common variants in the general CF population. p.Ala559Thr was
observed in 3% of Dominican patients in our study was not in the top
25 variants of the general CF population.1
The spectrum of CFTR variants varies between Latino populations
across the world and also varied between the two specific Latino
TABLE 2 Potentially disease‐causing variants
# Protein name cDNA name Position (GRCh38) Reference allele Alternate allele
Occurrences, n (%)
D.R. P.R.
Variants of varying clinical consequence
1 p.Arg74Trp c.220C>T 7:117509089 C T 1 (2%) 1 (5%)
2 ‐‐‐ c.1210‐34TG[11]T[5] 7:117548628 GTT G 2 (3%) ‐‐‐
3 ‐‐‐ c.1210‐34TG[12]T[5] 7:117548630 T G 1 (2%) ‐‐‐
4 p.Asp1270Asn c.3808G>A 7:117642528 G A ‐‐‐ 1 (5%)
Variants of uncertain significance
1 ‐‐‐ c.‐226G>T 7:117479869 G T 1 (2%) ‐‐‐
2 p.Val201Met c.601G>A 7:117535269 G A ‐‐‐ 1 (5%)
3 p.Ser589Asn c.1766G>A 7:117590439 G A 1 (2%) ‐‐‐
4 p.Tyr1014Cys c.3041A>G 7:117610571 A G 1 (2%) ‐‐‐
5 p.Arg1158Gln c.3473G>A 7:117627526 G A 1 (2%) ‐‐‐
6 p.Asp1445Asn c.4333G>A 7:117666998 G A 1 (2%) ‐‐‐
Variants predicted to be deleterious
1 ‐‐‐ n.49‐4832T>G 7:117470859 T G 3 (5%) ‐‐‐
2 ‐‐‐ c.3674084T>G 7:117711674 T G 3 (5%) ‐‐‐
3 ‐‐‐ c.1585‐1361A>G 7:117586378 A G 1 (2%) ‐‐‐
4 ‐‐‐ n.‐2799A>G 7:117710954 A G 1 (2%) ‐‐‐
Abbreviations: cDNA, complementary DNA; D.R., Dominican Republic; P.R., Puerto Rico.






2 CF‐disease causing, trans 6 (10%) 17 (81%)
2 CF‐disease causing, cis 1 (2%) 1 (5%)
2 VVCC, 1 VUS, cis ‐‐‐ 1 (5%)
1 VUS, 1 predicted, cis 1 (2%) ‐‐‐
2 Predicted, cis 3 (5%) ‐‐‐
1 VVCC, 1 VUS, cis 1 (2%) ‐‐‐
1 CF‐causing 1 (2%) ‐‐‐
1 VVCC 3 (5%) ‐‐‐
1 VUS 2 (3%) ‐‐‐
1 Predicted 1 (2%) ‐‐‐
No variants 42 (69%) 2 (10%)
Note: CFTR variants were categorized using three functional annotation
databases as well as three computational tools for predicting
deleteriousness. Cis and trans describe the relationship between two or
more variants; cis refers to variants on the same gene copy while trans
describes variants on different gene copies.
Abbreviations: CF, cystic fibrosis; VVCC, variant of varying clinical
consequence; VUS, variant of uncertain significance.
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populations we studied: Dominicans and Puerto Ricans. In patients
with CF in Spain, the most frequent CFTR variants were p.Phe508del
(52%), p.Gly542x (8%), p.Asn1303Lys (3%), and 3849 + 10kbC→T
(2%).26 In Latino patients with CF from across the U.S., the most
frequent variants were p.Phe508del (37%), p.Gly542x (11%), and
p.Arg334Trp (11%),27 but most frequent variants differed across the
U.S. In the Southwestern U.S., the most frequent CFTR variants were
p.Phe508del (47%), p.Gly542x (5%), and 3849 + 10kbC→T (3%),28
which was similar to the pattern observed in Southern California:
p.Phe508del (52%), p.Gly542x (4%), 3849 + 10kbC→T (4%), and
p.Ser549Asn (2%).29 In Illinois, the most frequent variants were
p.Phe508del (52%), 3849 + 10kbC→T (7%), and p.Phe311del (7%).4
p.Phe508del was observed at a lower frequency in Dominican
patients (10%) and Puerto Rican patients (33%) in this study than in
the Latino populations described above. 3849 + 10kbC→T, a frequent
variant in all referenced Latino populations, was not found in any
patient in our study, which may be due to low frequencies in other
Hispanic populations (2%‐3%). p.Gly542X, one of the most frequent
variants in Latino populations, was not present at all in Dominicans
and observed only in 10% of Puerto Rican patients. The unique
spectrum of CFTR variants in Dominican and Puerto Rican patients
may be due to their heterogeneous genetic background, with a higher
proportion of African ancestry than in Latino populations from the
mainland U.S.8 Our findings highlight the need for investigating
population‐specific CFTR variants.
In this comprehensive genetic analysis of patients with clinically
confirmed CF, 81% of Puerto Rican patients had disease‐causing
CFTR variants identified on both chromosomes compared with only
10% of the Dominican patients. Over two‐thirds of Dominican
patients had no identifiable variant in CFTR compared with 10% of
Puerto Rican patients. We were surprised at the high proportion of
Dominican patients without any identifiable CFTR variants. In
contrast, sequencing analysis in other Latino populations with CF
have reported much higher detection rate (approximately 95%) of
CFTR variants.4,26 All the patients included in our study had clinical
evidence of CFTR dysfunction with symptoms consistent with CF and
a sweat chloride concentration of greater than 60mmol/L. Analysis
of nasal potential difference and functional analysis of the CFTR
channel may increase our understanding of CFTR function in patients
lacking CFTR variants. Other studies have described patients with
symptoms of CF and elevated sweat chloride concentrations but
without evidence of CFTR variants.30,31 Patients without 2 CFTR
variants in trans may have variants in other genes such as the
epithelial sodium channel (ENaC) or may have defective pathways
that lead to CFTR dysfunction.32
We were also surprised that 10% of Dominican and 10% of
Puerto Rican patients had multiple variants found on only one
chromosome (ie, in cis). Genotype phase is not routinely analyzed in
clinical sequencing of CFTR, so deleterious effects of different
variants in cis may be more common in the general CF population
than currently understood.
Understanding the spectrum and frequency of CFTR variants in
diverse populations is important for improving CF genetic panels and
newborn screening programs. Genetic panels and newborn screening
programs are generally developed based on variant frequencies
observed in the White population and have lower sensitivity (ie,
higher false negative rate) when applied to a Latino population. The
American College of Medical Genetics (ACMG)/American College of
Obstetricians and Gynecologists (ACOG)‐recommended CFTR 23
variant panel offered to pregnant women has a 76% detection rate in
White patients with CF, while the detection rate is only 48% in Latino
patients with CF.5,33 The ACOG panel would have detected only 7 of
the 30 variants that we identified in our study (five variants in
Dominicans, six variants in Puerto Ricans). Using the ACOG panel in
our patients, 73% of patients would have no variants identified and
15% would have had only one variant identified.
Genetic screens and newborn screens should be sensitive to the
target population and include the prevalent CFTR variants for all
racial and ethnic groups to minimize false negative diagnoses.
Detection via newborn screening is important as patients diagnosed
via newborn screen demonstrate improved lung function and
nutritional status compared with those not detected on a newborn
screen.34 In the Illinois newborn screen, for example, Latino infants
were more likely to have undefined variants and twice as likely to
have only one variant identified compared to White infants.4 Latino
patients have both more rare and novel CFTR variants so newborn or
genetic screens will always be less effective for Latino patients if they
do not include sequencing.35,36
CFTR genetic variant identification and functional classification
have become increasingly valuable not only for CF phenotype
prediction but also for identifying those patients who would benefit
from CFTR modulator therapies.37 CFTR modulators target specific
CFTR variants, which occur more frequently in White patients
compared with minorities. As a result, only a third of Latino patients
qualify compared with three‐quarters of White patients.38 This is
consistent with our studyʼs findings that only 5 of 82 patients (three
Dominicans and two Puerto Ricans) were eligible for CFTR
modulator pharmacotherapy. Only two of the 30 variants we
identified were eligible CFTR modulator targets: p.Phe508del and
p.Arg74Trp. The most common variant in Puerto Rican patients,
p.Arg1066Cys, is not approved for CFTR modulators. To combat
this disparity in access to life‐altering pharmacogenetic therapies,
the first step is to identify CFTR variants in CF populations, as we
have done in this study, and then to describe the functional
implications of the identified variants and investigate the protein
response to CFTR modulators. The final step is to include Latino and
other non‐Latino non‐White patients in clinical trials of CFTR
modulators, as minorities are underrepresented in the majority of
CF pharmacotherapy clinical trials.39
In silico prediction algorithms have been used to identify likely
disease‐contributing CFTR variants, but the utility of predictive
algorithms is controversial as they cannot differentiate between
variants that caused severe, moderate, or minimal reduction in
CFTR function.40-42 Our study similarly found inconsistent predic-
tions as the algorithms predicted five variants to be deleterious
but were annotated by CFTR2 as “non‐CF‐causing” (Table S1).
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Additionally, we identified three variants that were predicted to be
deleterious but were removed after manual inspection of the
sequencing reads alignment.
Although we sequenced the majority of known patients with CF
over 6 years old in both Puerto Rico and the Dominican Republic, our
study was limited by a small number of patients. To fully understand
CFTR variants in these populations, a genetic analysis of the general
population of the Dominican Republic and Puerto Rico is needed. Our
study identified multiple variants in cis, but our study was not
designed to genotype parents to confirm genotype phase.
Our study results indicate that the spectrum of CFTR variants in
an unstudied CF population cannot be inferred from another CF
population, even if the racial and ethnic background is similar.
Genetic panels and even genome sequencing have limitations in
identifying CFTR variants in Latino patients with CF. Understanding
the spectrum of CFTR variants in all populations with CF is the first
step towards developing effective CF treatment for all patients.
Studies of cystic fibrosis and pharmacotherapies need to include
more racially diverse populations to make precision medicine
socially precise.
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